Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE) two randomised, double-masked, phase 3, non-inferiority trials /

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE) two randomised, double-masked, phase 3, non-inferiority trials /

Saved in:
Bibliographic Details
Main Authors: Heier Jeffrey S.
Khanani Arshad M.
Ruiz Carlos Quezada
Basu Karen
Ferrone Philip J.
Brittain Christopher
Figueroa Marta S.
Lin Hugh
Holz Frank G.
Patel Vaibhavi
Lai Timothy Y. Y.
Silverman David
Tóth-Molnár Edit
Zatorska Barbara
Kollaborációs szervezet: TENAYA and LUCERNE Investigators
Format: Article
Published: The Lancet Publishing Group 2022
Series:LANCET 399 No. 10326
Subjects:
Szemészet
doi:10.1016/S0140-6736(22)00010-1

mtmt:32786392
Online Access:http://publicatio.bibl.u-szeged.hu/24214
Description
Physical Description:729-740
ISSN:0140-6736

Similar Items